10 results about "Pleuropneumonia" patented technology

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The invention belongs to the technical field of biology, and particularly relates to a nasal spray sheep contagious pleuropneumonia subunit vaccine and a preparation method thereof. Comprising a first antigen protein and a second antigen protein, the amino acid sequence of the first antigen protein is shown as SEQ NO: 1, and the amino acid sequence of the second antigen protein is shown as SEQ NO: 2. The mass ratio of the first antigen protein to the second antigen protein is 1: (1-1.5). Ca < + > can stabilize an antigen protein structure through an ionic bond and reduce degradation of the antigen protein in nasal mucosa secretions, when tannic acid is combined with a Ca < + >-antigen compound, a more ordered immunogenic compound can be formed through the synergistic effect of polyphenol-metal ion-protein, so that part of antigen is changed into particles, and the stability of the antigen is improved. PDA can wrap a compound, firm attachment is formed in a nasal mucosa moist environment by means of the bionic adhesion characteristic of PDA, the antigen exposure time is prolonged, and continuous generation of antibodies is promoted.

This invention relates to the field of molecular biology, specifically to a nested PCR primer set, kit, and application for detecting porcine infectious pleuropneumonia. The kit, developed by establishing a nested PCR amplification primer set, can be used for the in vitro diagnosis of porcine infectious pleuropneumonia. It exhibits high sensitivity, detecting up to 0.355 pg / µL, which is nearly 100 times higher than that of conventional PCR (35.5 pg / µL). It also demonstrates strong specificity, overcoming the problems of low sensitivity and poor specificity associated with conventional PCR. Compared to existing indirect immunofluorescence and serological detection methods, it offers lower cost and a shorter detection cycle.

The invention provides a water-soluble tilmicosin premix for treating pleuropneumonia, mycoplasma infection and ileitis and a preparation method of the water-soluble tilmicosin premix, and belongs to the field of medicaments for livestock and poultry. The water-soluble tilmicosin premixing agent is prepared from tilmicosin base, modified chitosan, citric acid, polyvinylpyrrolidone, polyethylene glycol 6000, poloxamer 188, lactose, silicon dioxide and hydroxypropyl-beta-cyclodextrin. The modified chitosan is prepared by grafting vitamin E succinate and quaternary ammonium salt chitosan, has amphipathy, can effectively embed tilmicosin, and improves the water solubility and stability of tilmicosin. The water-soluble tilmicosin premix disclosed by the invention is good in water solubility, good in palatability and high in bioavailability, can be administrated in a water drinking or material stirring manner, and can be used for treating pleuropneumonia, mycoplasma infection and ileitis of livestock and poultry such as pigs and chickens.

This invention discloses a Mycoplasma caprineis subspecies Mccp NM strain and its applications. Whole-genome alignment of this strain revealed 422 missense mutations, 132 frameshift mutations, and several key insertion / deletion variations compared to the existing vaccine strain C87001. In virulence studies, at a concentration of 1×10⁻⁶... 9 In healthy, susceptible goats, intratracheal injection at a CCU / mL dose resulted in all experimental goats exhibiting typical symptoms of caprine contagious pleuropneumonia. Autopsy revealed pleural effusion and liver-like lesions in the lungs. The inactivated vaccine prepared using this strain demonstrated good safety in goats. Challenge protection tests showed that the vaccine of this invention provided 100% protection against homologous challenge with the NM strain and 80% protection against the heterologous C87002 strain, while commercially available vaccines offered only 40% protection against the NM strain. This invention overcomes the deficiency of existing vaccines in providing insufficient protection against clinical variants, offering an effective technical reserve and candidate vaccine for addressing immunization failure caused by Mccp antigen mutations.

The application discloses a competitive ELISA detection kit for bovine contagious pleuropneumonia and application thereof. The kit contains a monoclonal antibody secreted by a hybridoma cell strain with a microbial preservation number of CGMCC NO.45502 and an antigen-coated ELISA plate composed of amino acids 29 to 166 in the extracellular region of a small colony false protein of Mycoplasma mycoides subsp. mycoides (Mmm). The application successfully screens a candidate diagnostic marker protein through a whole protein analysis method of Mycoplasma mycoides subsp. mycoides (Mmm). A detection method established by screening a monoclonal antibody with the protein can specifically detect CBPP positive serum and has no cross reaction with other related disease positive serum. The competitive ELISA detection method established by the application has a specific property equivalent to that of a WOAH recommended method and a sensitivity about 25% higher than that of the WOAH recommended method. The application provides an effective technical means for detection of bovine contagious pleuropneumonia.

This invention relates to the fields of veterinary immunology and molecular biology, and discloses a goat cytokine composition with immune-enhancing effects and its applications. The composition comprises recombinant goat cytokines IL-9 and IL-21, whose amino acid sequences are shown in SEQ ID NO. 8 and SEQ ID NO. 12, respectively. These two cytokines upregulate the expression of IL-2, IL-4, IFN-γ, IL-17, and TNF-α in goat PBMCs, stimulating Th1, Th2, and Th17 immune responses in goats. When used in combination with an inactivated goat infectious pleuropneumonia vaccine, this goat cytokine composition exhibits good immune-enhancing effects and shows potential application prospects. This goat cytokine composition has advantages such as ease of preparation, high yield, good stability, and low production cost.

This invention belongs to the field of biotechnology, specifically relating to a nasal spray subunit vaccine for ovine infectious pleuropneumonia and its preparation method. It includes a first antigen protein and a second antigen protein, the amino acid sequence of which is shown in SEQ NO:1, and the amino acid sequence of which is shown in SEQ NO:2. The mass ratio of the first antigen protein to the second antigen protein is 1:(1-1.5). This invention [Ca²] + It can stabilize the structure of antigen proteins through ionic bonds, reducing their degradation in nasal mucosal secretions. Tannic acid and Ca²⁺ + When antigen complexes bind, they can form more ordered immunogenic complexes through the synergistic effect of polyphenols, metal ions, and proteins, making some antigens particulate and enhancing the uptake and processing efficiency of antigen-presenting cells. PDA can encapsulate the complex and use its biomimetic adhesion properties to form a firm attachment in the moist environment of the nasal mucosa, prolonging the antigen exposure time and promoting the continuous production of antibodies.

The invention relates to the technical field of sheep contagious pleuropneumonia diagnosis, and discloses a method for detecting mycoplasma ovipneumoniae based on a multi-enzyme constant-temperature nucleic acid rapid amplification technology (MIRA), which comprises the following steps: extracting DNA of a sample to be detected; taking the DNA as a template, and carrying out MIRA amplification reaction by using a specific primer pair and a probe; an upstream primer sequence of the primer pair is as shown in SEQ ID NO: 1, and a downstream primer sequence is as shown in SEQ ID NO: 2; the probe sequence is shown as SEQ ID NO: 3, the 5'end of the probe is marked with an FAM fluorophore, the 3 'end of the probe is marked with a BHQ1 quenching group, and a tetrahydrofuran (THF) site is inserted into the position 30-35 nt away from the 5' end; reacting for 20-25 minutes at the constant temperature of 41 DEG C, and monitoring a fluorescence signal in real time. According to the invention, a multi-enzyme constant-temperature nucleic acid rapid amplification technology (MIRA) is applied to on-site rapid detection of mycoplasma ovipneumoniae (Mo) for the first time, and the technical bottlenecks that traditional PCR depends on expensive instruments, is complex to operate and consumes long time are broken through.

The invention relates to the technical field of veterinary immunology and molecular biology, and discloses a goat cytokine composition with an immunological enhancement effect and application thereof, the goat cytokine composition with the immunological enhancement effect comprises recombinant goat cytokines IL-9 and IL-21, and amino acid sequences of the recombinant goat cytokines are respectively shown as SEQ ID NO.8 and SEQ ID NO.12. The goat cytokine composition with the immunological enhancement effect comprises recombinant goat cytokines IL-9 and IL-21. The two cytokines provided by the invention can up-regulate expression IL-2, IL-4, IFN-gamma, IL-17 and TNF-alpha of goat PBMC (peripheral blood mononuclear cells), and have a stimulation effect on Th1, Th2 and Th17 type immune responses of goats. The goat cytokine composition is combined with a goat contagious pleuropneumonia inactivated vaccine for use, shows a better immunological enhancement effect, and has a potential application prospect. The goat cell factor composition has the advantages of being easy to prepare, high in yield, good in stability, low in production cost and the like.